AGER and lung carcinoma: In lung cancer, the serum sRAGE level was found to be decreased during lung cancer progression and could reflect decreased RAGE expression in tissue, suggesting that the serum sRAGE may be a pivotal diagnostic biomarker for lung cancer.55